A-Alpha Bio, a Seattle-based biotechnology company, announced the Department of Defense has awarded the company another $14.5M to accelerate its antibody discovery and optimize for biothreats.
According to A-Alpha Bio cofounder and CEO, David Younger, PHD, “We’ve measured 10 million interactions in this collaboration and have focused so far on three pathogenic families. This extension of funding will allow us to really broaden both our potential impact on pandemic preparedness and our interest in training more generalizable models. Having an interaction space that covers more pathogen diversity is exactly what we’re interested in doing.”